The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
Primaquine binds to and results in increased activity of AHR protein [Primaquine results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Primaquine results in increased expression of CYP1A1 protein]; Primaquine binds to and results in increased activity of AHR protein; Primaquine inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]
Primaquine results in increased activity of CYP1A1 promoter; Primaquine results in increased activity of CYP1A1 protein Primaquine results in increased expression of CYP1A1 mRNA; Primaquine results in increased expression of CYP1A1 protein [Primaquine results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Primaquine results in increased expression of CYP1A1 protein]; Primaquine binds to and results in decreased activity of CYP1A1 protein Primaquine results in decreased degradation of CYP1A1 protein CYP1A1 protein results in increased susceptibility to Primaquine Primaquine results in decreased activity of CYP1A1 protein
Primaquine results in increased activity of CYP1A2 promoter CYP1A2 protein affects the metabolism of Primaquine Primaquine results in increased expression of CYP1A2 mRNA [CYP1A2 protein results in increased expression of HBG2 protein] which affects the susceptibility to Primaquine CYP1A2 protein results in increased metabolism of Primaquine
[CYP2B6 protein results in increased expression of HBG2 protein] which affects the susceptibility to Primaquine CYP2B6 protein results in increased metabolism of Primaquine
[CYP2D6 protein results in increased expression of HBG2 protein] which affects the susceptibility to Primaquine CYP2D6 protein affects the metabolism of Primaquine CYP2D6 protein results in increased metabolism of Primaquine CYP2D6 protein results in increased susceptibility to Primaquine
CYP2E1 protein results in increased metabolism of Primaquine [CYP2E1 protein results in increased expression of HBG2 protein] which affects the susceptibility to Primaquine
CYP3A4 protein results in increased metabolism of Primaquine [CYP3A4 protein results in increased expression of HBG2 protein] which affects the susceptibility to Primaquine